logo
US retailer Dick's to acquire Foot Locker in $2.4 billion deal

US retailer Dick's to acquire Foot Locker in $2.4 billion deal

Fibre2Fashion15-05-2025

DICK'S Sporting Goods, Inc. ("DICK'S") (NYSE: DKS), a leading U.S. based full-line omni-channel sporting goods retailer, and Foot Locker, Inc. ("Foot Locker") (NYSE: FL), a leading footwear and apparel retailer, announced that they have entered into a definitive merger agreement under which DICK'S will acquire Foot Locker. This transaction implies an equity value of approximately $2.4 billion and an enterprise value of approximately $2.5 billion.
Dick's Sporting Goods will acquire Foot Locker in a $2.4 billion deal, operating it as a standalone unit. The merger expands Dick's global reach, adds ~2,400 stores, and boosts presence in sneaker culture. It aims to drive growth through omnichannel retail, enhance brand partnerships, and achieve $100â€'$125 million in synergies while serving a broader consumer base.
Foot Locker has a strong history of sneaker expertise that sparks discovery and ignites the power of sneaker culture through its portfolio of brands, including Foot Locker, Kids Foot Locker, Champs Sports, WSS, and atmos. It encompasses approximately 2,400 retail stores across 20 countries in North America, Europe, Asia, Australia and New Zealand, and a licensed store presence in Europe, the Middle East and Asia. In 2024, Foot Locker achieved net worldwide sales of $8 billion. DICK'S expects to operate Foot Locker as a standalone business unit within its portfolio and maintain the Foot Locker brands.
"We have long admired the cultural significance and brand equity that Foot Locker and its dedicated Stripers have built within the communities they serve," said Ed Stack, Executive Chairman of DICK'S. "We believe there is meaningful opportunity for growth ahead. By applying our operational expertise to this iconic business, we see a clear path to further unlocking growth and enhancing Foot Locker's position in the industry. Together, we will leverage the complementary strengths of both organizations to better serve the broad and evolving needs of global sports retail consumers."
"We look forward to welcoming Foot Locker's talented team and building upon their expertise and passion for their business, which we intend to honor and amplify together," said Lauren Hobart, President and CEO of DICK'S. "Sports and sports culture continue to be incredibly powerful, and with this acquisition, we'll create a new global platform that serves those ever-evolving needs through iconic concepts consumers know and love, enhanced store designs and omnichannel experiences, as well as a product mix that appeals to our different customer bases."
"Today's announcement marks the start of an exciting new chapter for Foot Locker and is a testament to our team's hard work and dedication to our mission," said Mary Dillon, CEO of Foot Locker. "By joining forces with DICK'S, Foot Locker will be even better positioned to expand sneaker culture, elevate the omnichannel experience for our customers and brand partners, and enhance our position in the industry. We are pleased to provide shareholders with a transaction structure that offers the choice of significant and immediate cash value or the opportunity to invest in the combined company and benefit from the substantial upside potential. I am proud of all that our teams around the world, including our Stripers, have accomplished to reach this milestone moment, and am confident this transaction represents the best path for our shareholders and other stakeholders."
The proposed acquisition represents an important strategic milestone for DICK'S whereby the combined company offers significant strategic and financial benefits:
Create a global platform within the growing sports retail industry. The transaction will better position the combined company to serve consumers worldwide and expands DICK'S addressable market opportunity. By combining with Foot Locker, DICK'S will be poised to serve consumers not only in new locations in the U.S. through Foot Locker's complementary real estate portfolio, but also internationally for the first time. With strong long-term industry tailwinds, the combined company is well positioned for long-term growth.
Serve a broader set of consumers across differentiated concepts. Iconic concepts will cater to a broad spectrum of consumers, from performance-focused athletes to sneakerheads. Building upon the groundbreaking learnings from DICK'S House of Sport and Foot Locker's Reimagined Concept stores, the combined company will provide an unmatched immersive and innovative retail experience for consumers.
Strengthen relationships with brand partners through global reach. Together, DICK'S and Foot Locker will serve as a stronger partner for key brands, offering multiple platforms for both established and emerging partners to showcase their assortments, connect with athletes and increase visibility on a global level.
Invest in future growth through an industry-leading omnichannel experience. DICK'S has a history of strong growth and aims to invest in and grow the Foot Locker brand and position the combined company for long-term success. The combination will drive growth through differentiated store concepts and robust digital experiences to enable sustainable long-term profitable growth. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged.
Fibre2Fashion News Desk (HU)

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Majority of Indian manufacturers investing in AI to manage uncertainty: Rockwell report, ET Manufacturing
Majority of Indian manufacturers investing in AI to manage uncertainty: Rockwell report, ET Manufacturing

Time of India

time3 hours ago

  • Time of India

Majority of Indian manufacturers investing in AI to manage uncertainty: Rockwell report, ET Manufacturing

Advt Advt Advt By , ETManufacturing Join the community of Top industry professionals Subscribe to our newsletter to get latest insights & analysis. Get updates on your preferred social platform Follow us for the latest news, insider access to events and more. A new global study from Rockwell Automation, Inc. has found that 99 per cent of Indian manufacturers have either invested in or plan to invest in artificial intelligence and machine learning ( AI/ML ) technologies over the next five years. The findings are part of the company's 10th annual State of Smart Manufacturing Report , based on feedback from 1,560 respondents across 17 major manufacturing report highlights how manufacturers are adopting smart technologies to improve operations and manage risks amid ongoing economic changes. For Indian companies, long-term business impact was cited by 81 per cent of respondents as the primary motivation for adopting advanced Sawhney, Managing Director, Rockwell Automation India , said, 'This year's report underscores the growing influence of advanced technologies on Indian manufacturing. Indian organisations are adapting to fast evolving global manufacturing, economic shifts, and supply chain dynamics. AI and machine learning technologies, once seen as emerging trends, have now evolved into strategic priorities, with nearly every Indian manufacturer seeing value in investing in these technologies.'The report also found that India n manufacturers are utilising 53 per cent of their collected data effectively, outperforming the global average of 44 per cent. Employers in India are placing emphasis on workforce skills such as analytical thinking and teamwork, aligning with the requirements of increasingly digital sustainability, 94 per cent of Indian respondents said they have some form of formal sustainability programme in place, with a strong focus on energy management and integrating environmentally responsible processes across product 95 per cent of manufacturers have invested in or plan to invest in AI/ML within five years. Investment in generative and causal AI has increased by 12% year-on-year. Cybersecurity remains a growing concern, with 49 per cent of respondents planning to deploy AI for cybersecurity in 2025—up from 40 per cent in trends include 48 per cent of manufacturers planning to repurpose or hire workers as a result of smart manufacturing investments, and 41 per cent turning to AI and automation to address labour shortages. Quality control remains the leading AI use case for a second consecutive year, with half of all respondents planning to use AI to support product progress, challenges persist. The ability to apply AI is now considered an essential skill by nearly 50 per cent of manufacturers, up from 10 per cent last year, indicating that the demand for AI capability is rising across all organisational full report, conducted by Rockwell Automation in partnership with Sapio Research , covers perspectives from multiple industries, including automotive, food and beverage, energy, and life sciences.

Stablecoin bigwig Circle soars in debut on the New York Stock Exchange
Stablecoin bigwig Circle soars in debut on the New York Stock Exchange

Economic Times

time6 hours ago

  • Economic Times

Stablecoin bigwig Circle soars in debut on the New York Stock Exchange

The US-based issuer of one of the most popular cryptocurrencies made its debut on the New York Stock Exchange on Thursday and quickly saw its value soar amid heavy interest from crypto enthusiasts and investors. Circle Internet Group issues USDC, a stablecoin that can be traded at a 1-to-1 ratio for US dollars, and EURC, which can similarly be traded for euros. Stablecoins are a fast-growing corner of the cryptocurrency industry that offer a buffer against volatility because they are pegged to real-world assets, like US dollars or gold. That makes them a much more reliable means of conducting commercial transactions than other forms of crypto. Interest in Circle's initial public offering is high. The company's underwriters priced the offering at $31 per share Wednesday, up from an expected range of $27 to $28. The number of shares being sold was raised to 34 million from 32 million. Circle is listed on the NYSE under the symbol "CRCL." The stock price soared above $96 at one point Thursday afternoon and landed at $83.23 by closing. Circle's initial public offering is one of the biggest public listings for a crypto-related company since the exchange Coinbase went public in 2021. The dominant player in the stablecoin field is El Salvador-based Tether, which has the stablecoin known as USDT that currently has about $150 billion in circulation. USDC is the second most popular stablecoin market cap, with about $60 billion in circulation. Circle said in a regulatory filing that USDC has been used for more than "$25 trillion in onchain transactions" since its launch in 2018. Revenue-wise the company has seen tremendous growth, going from just $15 million in 2020 to $1.7 billion in 2024. Stablecoin issuers make profits by collecting the interest on the assets they hold in reserve to back their stablecoins. Circle said USDC is backed by "cash, short-dated US Treasuries and overnight US Treasury repurchase agreements with leading global banks." Circle's IPO comes amid a push by the Trump administration and the crypto industry to pass legislation that would regulate how stablecoin issuers operate in the US A Senate bill advanced last month with bipartisan support. There is also growing competition in the stablecoin field. A crypto enterprise partly owned by the Trump family just launched its own stablecoin, USD1. Circle said its long track record and values - the company says its mission statement is "to raise global economic prosperity through the frictionless exchange of value" - will help it stand apart in the field.

Dr. Reddy's shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar
Dr. Reddy's shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar

Time of India

time7 hours ago

  • Time of India

Dr. Reddy's shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar

Shares of Dr. Reddy's Laboratories rose 1.4% to touch the day's high of Rs 1,307.65 on the BSE on Friday, June 6, after the company announced a strategic collaboration with Alvotech , a global biotech firm, to co-develop and commercialize a biosimilar candidate to Keytruda ( pembrolizumab ) for global markets. 'Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines, and Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's'), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets,' Dr. Reddy's said in an exchange filing. Keytruda, a leading immunotherapy drug used in the treatment of various cancers, generated $29.5 billion in global sales in 2024, making it one of the most valuable targets in the biosimilars market. This partnership represents a significant opportunity for Dr. Reddy's to enter the high-value biosimilar segment for oncology drugs, a category that continues to witness growing demand and heightened competitive activity. Under the agreement, both parties will jointly develop and manufacture the biosimilar, sharing costs and responsibilities. Importantly, each company will retain the right to commercialize the product globally, subject to certain exceptions. The deal is expected to accelerate development timelines and expand the global market reach of the biosimilar. Róbert Wessman, Chairman and CEO of Alvotech, emphasized that the agreement will help deliver cost-effective, critical biologic medicines to patients worldwide by combining Dr. Reddy's commercial strength with Alvotech's R&D and manufacturing expertise. With this collaboration, Dr. Reddy's further strengthens its pipeline in the biosimilars segment. 'We are pleased to collaborate with Alvotech on the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high-quality, affordable treatment options for patients across the world. Oncology has been a key focus area for us, and this collaboration will enhance our capabilities in this domain, as pembrolizumab represents one of the most critical therapies in immuno-oncology,' said Erez Israeli, CEO of Dr. Reddy's. Dr. Reddy's Laboratories shares ended Thursday's session higher by 3% at Rs 1,289.90 on BSE. Also read: Positive Breakout: These 5 stocks cross above their 200 DMAs ( Disclaimer : Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store